PCM
ZSAN

Prelude Capital Management’s Zosano Pharma Corporation ZSAN Stock Holding History

Prelude Capital Management’s Portfolio ZSAN Stock Details ZSAN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-14
Closed -$14K – 1983
2017
Q2 		$14K Buy
+14
New +$14.5K ﹤0.01% 1341

Other funds holding ZSAN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

Prelude Capital Management's ZSAN Position: Q3 2017 in Review

Prelude Capital Management sold out of Zosano Pharma Corporation (ZSAN) in Q3 2017, closing a stake of 14 shares — an estimated $14K sold.

Prelude Capital Management first reported a position in ZSAN in Q2 2017 and held it in 1 quarter. The position peaked at $14K in Q2 2017. 22 funds tracked by Wall St. Rank hold ZSAN as of Q3 2017.

  • Prelude Capital Management reported no remaining Zosano Pharma Corporation position as of Q3 2017 after selling out during the quarter.
  • Prelude Capital Management sold 14 Zosano Pharma Corporation shares in Q3 2017, an estimated $14K.
  • Prelude Capital Management first reported a position in Zosano Pharma Corporation in Q2 2017 and held it in 1 quarter.
  • Prelude Capital Management's Zosano Pharma Corporation position peaked at $14K in Q2 2017.
  • 22 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q3 2017.

Based on Prelude Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.